Your session is about to expire
← Back to Search
Transcutaneous CO2 monitoring for Neuromuscular Disease
N/A
Waitlist Available
Led By Reshma Amin, MD
Research Sponsored by The Hospital for Sick Children
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
Study Summary
This trial is testing whether an at-home carbon dioxide monitor can help diagnose nocturnal hypoventilation in children with neuromuscular disorders.
Eligible Conditions
- Neuromuscular Disease
- Central Sleep Apnea
- Obstructive Sleep Apnea
- Sleep Apnea
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 9 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Sensitivity and specificity of ambulatory, at home, transcutaneous CO2 (tcCO2) monitoring to diagnose nocturnal hypoventilation as compared to the gold standard, end tidal CO2 conducted during polysomnogram (PSG).
Secondary outcome measures
a) Agreement of tcCO2 monitoring when worn in the ambulatory, at home, setting compared to tcCO2 recorded during a PSG in a hospital based sleep laboratory for diagnosis of nocturnal hypoventilation.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Transcutaneous CO2 monitoringExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
The Hospital for Sick ChildrenLead Sponsor
692 Previous Clinical Trials
6,946,561 Total Patients Enrolled
Reshma Amin, MDPrincipal InvestigatorStaff Physician
2 Previous Clinical Trials
43 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger